Ophthalmic Drugs Contract Manufacturing Market to Record an Exponential CAGR by 2030

Roots Analysis has done a detailed study on Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

Get Detailed Analysis:  https://www.rootsanalysis.com/reports/view_document/ophthalmic-drugs-cmo/294.html

Key Market Insights

• Over 240 companies across the globe claim to have the required capabilities to offer variety of services on a contract basis, working at different scales of operation, for a wide range of ophthalmic APIs and drug FDFs
• The market is fragmented, featuring the presence of both established players and small firms based in different geographies that claim to be capable of manufacturing ophthalmic products
• Presently, majority of the CMOs are offering services for ophthalmic drug FDFs packaged in a variety of formats; popular types of containers include glass / plastic bottles, ointment tubes and ampoules / vials
• In order to acquire competencies across the supply chain and cater to evolving needs of sponsors, companies have established presence across different regions, having been certified by various regulatory authorities
• Several players involved in this domain are steadily expanding their capabilities in order to enhance their respective service portfolios and maintain a competitive edge
• In the past few years, over 10,700 trials, enrolling approximately 4.6 million patients, suffering from a wide range of chronic eye conditions, have been registered across the globe by different sponsors
• Most of the installed, global ophthalmic drug manufacturing capacity belongs to larger and more established CMOs, accounting for over 80% of available capacity across various geographies
• The demand for manufacturing services for ophthalmic drug products is expected to increase in the coming years; we believe stakeholders may have to expand their respective capacities to ensure consistent supply
• We expect ophthalmic drug developers to continue to outsource their development and manufacturing operations in the short to mid-term, causing service-based revenues to grow at an annualized rate of over 8%
• In the long-term, the projected opportunity is anticipated to be well distributed across various packaging formats, scales of operation and sizes of contract service providers
• Eminent representatives from prominent ophthalmic drug contract manufacturing companies confirm the importance of outsourcing, highlighting prevalent and anticipated trends within this domain

Type of product

• Ophthalmic API
• Ophthalmic drug FDF

Type of FDF manufactured

• Solid
• Semi-solid
• Liquid / suspension

Type of primary packaging

• Ampoule / vial 
• Glass / plastic bottle
• Ointment tube
• Blister packing
• Other forms

Scale of manufacturing

• Clinical
• Commercial

Company size

• Small
• Mid-sized
• Large
• Very large

Target disease indication

• Age-related macular degeneration
• Dry eye
• Glaucoma
• Other disease segments

Key geographical regions

• North America (US, Canada and Mexico)
• Europe (UK, Germany, France, Spain, Italy and rest of Europe)
• Asia-Pacific (India, China, Japan, Australia and rest of Asia-Pacific)
• Rest of the world

Request for Customization: https://www.rootsanalysis.com/reports/294/request-customization.html

The Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules), 2020-2030 report features the following companies, which we identified to be key players in this domain:

• Akorn
• Akums
• Bal Pharma
• Catalent
• Cayman Chemical
• Entod Pharmaceuticals
• Farmigea
• Glenmark Pharmaceuticals
• Indiana Ophthalmics
• Lomapharm
• Medichem
• Pillar5 Pharma
• Recipharm
• Salvat
• Sterling Pharmaceutical Services
• Sunways India

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Current Market Landscape

5. Company Competitiveness Analysis

6. Ophthalmic Drugs Contract Manufacturing in North America: Company Profiles

7. Ophthalmic Drugs Contract Manufacturing in Europe: Company Profiles

8. Ophthalmic Drugs Contract Manufacturing in Asia-Pacific: Company Profiles

9. Clinical Trial Analysis

10. Capacity Analysis

11. Demand Analysis

12. Market Forecast

13. Case Study: Comparison of Small Molecule and Large Molecule Ophthalmic Drugs / Therapies

14. SWOT Analysis

15. Survey Analysis

16. Executive Insights

17. Future Growth Opportunities

18. Appendix 1: List of Ophthalmic Medical Device Contract Manufacturers

19. Appendix 2: Tabulated Data

20. Appendix 3: List of Companies and Organizations

Get Latest PDF Sample of this Report:

https://www.rootsanalysis.com/reports/294/request-sample.html    

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

Also have a Look on Our Upcoming Research Reports

Soft Tissue Sarcoma: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031

Cloud-based Solutions for Drug Discovery, Development and Manufacturing Market Trends and Global Forecasts, 2021-2030

Spinal Muscular Atrophy Market, 2021-2031

Dravet Syndrome Market, 2021-2031

Hypertrophic Cardiomyopathy Market 2021-2031

Article source: https://article-realm.com/article/Finance/12501-Ophthalmic-Drugs-Contract-Manufacturing-Market-to-Record-an-Exponential-CAGR-by-2030.html